GenSight Biologics: Pioneering Mitochondrial & Neurodegenerative Eye Therapies
GenSight Biologics SA: Investing in mitochondrial & neurodegenerative disease therapies—trends, market data, and pipeline prospects for 2026.
2 minutes to read
GenSight Biologics SA
GenSight Biologics Raises €1.7M to Advance Gene Therapy for LHON
GenSight Biologics raises €1.7 m to fund its Phase III eye gene‑therapy GS010, boosting investor confidence in its fight against mitochondrial and neurodegenerative disorders.
2 minutes to read
GenSight Biologics: Rising Stock, Bold Mitochondrial & Neurodegenerative Research
GenSight Biologics SA, a clinical‑stage biotech, targets mitochondrial & neurodegenerative eye and CNS disorders, offering hopeful therapies amid volatile stock performance.
2 minutes to read
GenSight Biologics: Stable Euro Stock, Low Volatility, Low Valuation in Neurodegenerative Research
GenSight Biologics: low‑volatility biotech shares, €0.08 close, stable 52‑week range, focused on mitochondrial and neurodegenerative eye therapies.
2 minutes to read